• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

About Us

Syngene is an integrated research, development and manufacturing organisation providing scientific services – from early discovery to commercial supply. We offer services in a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies. Our culture of scientific innovation is driven by the expertise of our highly qualified team of 5,000 employees and supported by state-of-the-art infrastructure and market- leading technology.

We offer clients a customised end-to-end solution to fulfil their R&D and manufacturing requirements. This is underpinned by a well-established safety framework, track record of quality and compliance, robust supply chain and access to 5200+ scientists. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations due to our shared interest in the science and commitment to project delivery.

We recognise that trust is built incrementally project-by-project and we pride ourselves on the many deep, long-term client relationships that underpin our business and demonstrate the value of the work we do.

Our vision

To be a world-class partner delivering innovative scientific solutions

Our values

Integrity

To be ethical, honest and transparent in all we do

Excellence

To commit ourselves to the highest levels of scientific and operational excellence

Professionalism

To practise the highest degree of professionalism by fostering individual accountability, reliability, continuous improvement and customer focus

Our commitment

At Syngene, we aim to contribute to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges.

Clients

Deliver scientific innovation that meets our clients' requirements and, in turn, helps them to meet the needs of the people and patients they serve

Employees

Provide a safe work environment. Offer personal development in scientific, managerial and leadership skills to foster professional growth

Society & Environment

Safeguard the environment by reducing our environmental footprint and producing safe products and supporting the community around us

The Journey so far

At Syngene, we aim to contribute to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges. Here is a quick snapshot of our journey so far

2021
Expanded collaboration with BMS, Baxter and Amgen
2021
Expansion of Syngene’s integrated drug discovery (IDD) platform
2021
Laboratory capacity expansion in Bangalore, Hyderabad
2021
Capacity expansion in Mangalore for commercial API manufacturing
2021
Capacity and capability addition in Biologics manufacturing
2021
Signed a 10-year agreement with Zoetis for commercial manufacturing of Librela®, a first-of-its-kind monoclonal antibody to alleviate pain associated with osteoarthritis in dogs
2020
Commenced Phase I operations at Hyderabad
2020
GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider)
2020
COVID-19: Setting up of RT-PCR testing center
2020
Successfully completed unannounced US FDA inspection for Bio-analytical studies
2020
Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy
2020
Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order
2019
Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS)
2019
cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function
2018
Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas
2018
Received PMDA Accreditation
2018
Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
2018
Syngene expands collaboration with Baxter until 2024
2017
Strategic collaboration with Zoetis to develop and manufacture animal medicines
2017
Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
2017
Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2016
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, our fourth dedicated R&D center
2016
Crossed an annual turnover of Rupees 10,000 Million
2015
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India
2015
Clinigene International Limited amalgamated with Syngene
2014
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020
2014
Acceptance of manufacturing facility by the Department of Health & Human Services, FDA
2014
Established a 75,000 sq.ft center to provide stability and analytical services
2013
Crossed an annual turnover of over Rupees 5,000 million in Financial Year 2013
2013
Collaboration with Baxter International Inc. to establish the ‘Baxter Global Research Center', our third dedicated R&D center.
2013
Acceptance of our control testing laboratory by the Department of Health & Human Services, FDA.
2012
Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and our second dedicated R&D center.
2012
Certification of clinical facilities by ANVISA.
2012
Acquired 100% stake in Clinigene International Limited from Biocon.
2011
Endo Pharmaceuticals and our Company collaborated to develop novel biological therapeutic molecules against cancer.
2010
Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010
Initiated operations in formulation development.
2009
Dupont Crop Protection and our Company extended a partnership for R&D services.
2009
Expansion of manufacturing services with a new plant which is cGMP compliant.
2009
Initiated operations in safety assessment and large molecules development services.
2007
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Center
2007
Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007
Crossed an annual turnover of over Rupees 1,000 million in Financial Year 2007
2003
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2001
Forayed into chemical development with a dedicated manufacturing facility.
2000
Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
1999
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
1998
Granted 100% Export Oriented Unit (EOU) status by the Government of India
1994
Initiated operations as a CRO with services in chemistry and biology

Leadership

Jonathan Hunt

Managing Director and Chief Executive Officer

Jonathan holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene’s business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceuticals industry. Prior to joining Syngene in January 2016, he worked with Astrazeneca for over a decade where he has held various leadership positions including President & Director of Astrazeneca, Austria and President & COO, Astrazeneca India.

Mahesh Bhalgat

Chief Operating Officer

Mahesh holds a Ph.D. in Medicinal Chemistry from the University of Utah, the USA, and a bachelor’s degree in Pharmacy from the University of Mumbai. He has 30 years of experience in the biopharmaceutical, vaccine and pharma industries. Mahesh has worked and led different facets of R&D, analytical development, manufacturing and operations, technology transfer, regulatory sciences, quality and capital projects. During a 20-year US stint, he worked with Amgen, Monsanto, Celera Genomics and Molecular Probes (now Thermo Fisher). After moving to India, Mahesh was part of the team that brought WHO prequalification approvals for four vaccines in Biological E. Just before joining Syngene, he was the Chief Operating Officer at Shantha Biotechnics, a Sanofi company, where his responsibilities included operations, quality, supply chain, long-term strategic planning, manufacturing science and technology and human resources. Mahesh is a member of the CII National Committee on Technology, R&D and Innovation. At Syngene, Mahesh is the Chief Operating Officer and a member of the Executive Committee.

Ashu Tandon

Chief Commercial Officer

Ashu holds a BA (Economics) degree from the University of Delhi, India as well as a Post Graduate Diploma in International Marketing from the Delhi School of Economics. He completed his MBA from IMT Ghaziabad, India and has over 20 years experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting & outsourcing services in Research & Development. Ashu is based out of New Jersey and has global responsibility for Syngene’s commercial activities, including leading the business development team as well as developing new capabilities in marketing, brand building, digital & account management. As a member of the Executive Committee, he plays an important role in driving strategy as it relates to Commercial activities. Prior to joining Syngene, Ashu was at IQVIA (formerly QuintilesIMS), Infosys and Accenture.

Sibaji Biswas

Chief Financial Officer

Sibaji is a certified Chartered Financial Analyst (CFA) from ICFAI and holds a B.Tech from IIT- Kharagpur. With an MBA from University of Calcutta he has also completed Management Development Programs at Indian Institute of Management (IIM), Ahmedabad and London Business School. He has over 20 years of extensive experience in finance and related functions. His prior experience includes working with Vodafone (Romania), Vodafone (India), Hutchison Essar Limited, Fascel Limited, and the ABP Group. Prior to joining Syngene, he was the CFO and a member of the Board at Vodafone (Romania). At Syngene, he oversees the finance, supply chain, legal, secretarial and IT functions and as a member of the Executive Committee, he plays an important role in driving strategy, improving profitability, identifying new opportunities, improving cash generation and enabling organizational growth.

Sanjeev Sukumaran

Chief Human Resources Officer

Sanjeev is a Mechanical Engineer and holds a management degree from the Indian Institute of Management (IIM), Kozhikode and has done an Executive Leadership Program at INSEAD, Singapore. He has nearly 25 years of experience in the areas of strategic management, business advisory, sales and marketing, business development, client relationship management and team management across a range of sectors, including healthcare, life sciences, financial services, software and IT, FMCG, big data, supply chain management, e-commerce and shipping. Before joining Syngene, he held multiple senior-level positions at Thomson Reuters. He was also the former CEO of Force Fulcrum Solutions Pvt. Ltd. As CHRO, Sanjeev is a member of the Executive Committee (EC) and is responsible for talent acquisition, talent management, workforce management, employee value proposition, learning and development, employee engagement, rewards and recognition and succession planning.

Alok Mehrotra

Chief Quality Officer

Alok holds an M. Tech in Chemical Technology (Food Technology) from Harcourt Butler Technological Institute. He comes with more than 25 years of experience spread across Manufacturing Operations, Quality Assurance, Sustainability/EHS, Production, and Supplier Technical Assurance across varied industries. Over the years, Alok has worked with leading corporates, including Dr. Reddy’s, Reckitt Benckiser, Pepsi Foods Ltd,  Godrej Foods, and Beverages Ltd. In his recent assignment as Head of Global Quality Management at Dr. Reddy’s, he harmonized and integrated Quality management systems Globally and was also responsible for quality from all external suppliers and vendors. As Syngene’s CQO, Alok leads the Quality and Compliance function and will be in charge of initiatives to further strengthen our track record in quality and compliance

Kenneth Barr, Ph.D

Sr. Vice President – Discovery Services

Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis from the University of Texas. He has over two decades of experience in the areas of drug discovery for both small and large molecules and has been associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis. Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations at FORMA Therapeutics, where he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts, providing alliance management for key CRO relationships.

Alex Del Priore

Senior Vice President - Manufacturing

Alex has three decades of experience in developing, commercializing and life-cycle management of products in various life science industries. Holding positions in both the US and Europe, his experience includes senior roles with global P&L responsibility. Alex was Vice President Operations and Health COO at Johnson Matthey in Greater London in his last assignment. In addition, he has been instrumental in M&A, strategy development and new product introduction.

As a member of the Executive Committee, Alex plays a techno-commercial role, providing technical expertise to the API plant at Mangalore while building a sustainable client base for the business in collaboration with the commercial and business development teams. In addition, Alex is also responsible for biologics operations. Alex is based in Center Valley, Pennsylvania, USA.

Kiran Mazumdar Shaw

Non-Executive Chairperson

Ms. Shaw is a first-generation entrepreneur with over 44 years of experience in the field of biotechnology. She is a recipient of ‘Padma Shri’ and the ‘Padma Bhushan’ awards. She was also conferred with the highest French distinction – Chevalier de l’Ordre National de la Légion ’Honneur (Knight of the Legion of Honour) in 2016. She is ranked #1 in the Business Captains category in Global ‘Medicine Maker Power List’ 2018. Ms. Shaw is the only Indian in the Hurun Global Self-Made Women Billionaires List 2017. She is also the Chairperson and Managing Director of Biocon Limited, Independent Director on the Board of Infosys and United Breweries Ltd.

Jonathan Hunt

Managing Director and Chief Executive Officer

Jonathan holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene’s business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceuticals industry. Prior to joining Syngene in January 2015, he worked with Astrazeneca for over a decade where he has held various leadership positions including President & Director of Astrazeneca, Austria and President & COO, Astrazeneca India.

Professor Catherine Rosenberg

Non-Executive Director

Professor Rosenberg received her Diplomed’Ingénieur’ from the Ecole Nationale Superieure des Telecommunications de Bretagne and an M.S. (Computer Science)from the University of California. She also earned a ‘Doctorat en Sciences’ from the Universite de Paris XI. She is a Fellow Member of the Institute of Electrical and Electronics Engineers and was elected a Fellow Member of the Canadian Academy of Engineering in 2013. At present, Prof. Rosenberg is the Canada Research Chair in the Future Internet, the Cisco Research Chair in 5G Systems and a professor in electrical and computer engineering at the University of Waterloo, Canada. At Syngene, Professor Catherine Rosenburg is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.

Paul Blackburn

Independent Director

Mr. Blackburn is a graduate in Management Sciences from Warwick University, United Kingdom, and has a professional accounting qualification from Institute of Cost and Management Accountants, United Kingdom. With more than 40 years experience in the field of finance, he worked as senior finance executive at GlaxoSmithKline, UK. Currently, he is also on the Board of Mereo Biopharma Group Plc. At Syngene, Paul Blackburn is a Chairman of Audit Committee and Risk Management Committee, and a member of Stakeholders Relationship Committee.

Dr. Vijay Kuchroo

Independent Director

Dr. Kuchroo has a doctorate in Pathology from the University of Queensland, Australia. He is also the Samuel L. Wasserstrom Professor of Neurology at the Harvard Medical School, United States, and has 25 patents and over 325 research papers in immunology. He is a Member of the Scientific Advisory Boards of leading pharmaceutical companies including Pfizer, Novartis and GSK. He founded five different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. At Syngene, Dr. Vijay Kuchroo is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.

Vinita Bali

Independent Director

Ms. Bali is a global business leader with extensive experience in leading large companies both in India and overseas. She served as Chief Executive Officer/ MD of Britannia Industries from 2005 to 2014. Prior to that, she worked with eminent multinationals like The Coca- Cola Company and Cadbury Schweppes Plc in a variety of marketing, general management and chief executive roles across the globe. Ms. Bali serves as an advisory board member of PwC India and is a non-executive director on the boards of Smith & Nephew Plc, Bunge Limited and CRISIL. At Syngene, Vinita Bali is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.

Carl Decicco

Non-Executive Director

Dr. Carl P. Decicco, Ph.D., serves as the Chief Scientific Officer in Foghorn Therapeutics. Prior to joining Foghorn Therapeutics in 2018, he served as the Head of Discovery at Bristol-Myers Squibb (BMS) and was responsible for the discovery and advancement of drug candidates for clinical studies. He also had oversight of the Drug Safety Evaluation team that provided supporting studies for all levels of clinical investigation. He has 22 years of experience in the pharmaceutical industry. With his teams, he has delivered over 140 compounds into development, several of which have advanced into late stage clinical testing. He had been part of the BMS leadership team that has achieved 14 NDA’s over the last 10 years. He also serves as a Member of the Advisory Committee at Allied-Bristol Life Sciences, LLC. He completed post-doctoral studies with Professor EJ Corey at Harvard University, was a teaching fellow at the University of British Columbia and obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada. At Syngene, Dr. Carl P Decicco is a member of the Nomination and Remuneration Committee.

Sharmila Karve

Independent Director

Ms. Sharmila Abhay Karve is a Fellow member of the Institute of Chartered Accountants of India. She retired as audit partner from Price Waterhouse in June 2019. During her tenure in Price Waterhouse, she was an engagement partner with various large and prestigious Indian and multinational clients. She was the first female partner to be elected to the POC and to be appointed as the Chief Ethics Officer. In 2009 she was appointed as the Assurance Leader of the firm and was elevated to the role of Assurance Risk & Quality Leader in April 2012. In her assignment as Global Diversity Leader since December 2016, Ms Karve focused her efforts on bringing more diversity throughout the PwC network. At Syngene, Ms. Sharmila Abhay Karve is a member of the Audit Committee and Risk Management Committee and Chairman of the Stakeholders Relationship Committee.

Kush Parmar

Independent Director

Dr. Parmar holds a BA in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University, and an MD from Harvard Medical School. Currently, he is a Managing Partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco. Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. At Princeton University, Dr. Parmar worked on developmental genetics with Nobel Laureate Eric F. Wieschaus. A founding member of the COVID R&D alliance, Dr. Parmar also serves on the Boards of Akouos, Entrada, Homology, Rallybio and Vor Biopharma.

Our manufacturing and quality certifications

Certifications

We deliver our services with the highest regard for safety and regulatory compliance. Syngene has certifications from global regulatory authorities for our state-of-the-art facilities and across process and quality management systems.

Our manufacturing and quality certifications
The Principles of the Quality Management System adopted by our company

Quality management

Syngene is committed to offering various scientific research and development services that meet or exceed client expectations. All our services are in compliance with national and international regulatory requirements.

Syngene’s Approach To Environment Health Safety And Sustainability (EHSS)

Environment, Health, Safety & Sustainability

Syngene considers Environment, Health, Safety & Sustainability (EHSS) excellence as a top priority in all of its processes and is fully committed to achieving it in the most responsible manner.

Syngene’s Approach To Environment Health Safety And Sustainability (EHSS)
Our Research And Development Centers | Syngene CRO

Infrastructure

Syngene has world-class infrastructure with more than 1.87 million sq ft. of working space. Syngene strives to attract and retain the best talent in the industry and back them up with world class infrastructure and systems.

We pursue our Corporate Social Responsibility (CSR) with the same passion and responsibility as we do it with scientific research

Corporate Social Responsibility

We strive towards developing and sustaining healthy and empowered communities by improving the quality of life. We pursue Corporate Social Responsibility with the same passion and responsibility as scientific research.

Join Syngene.
Be at the cutting edge of Scientific Innovation

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details